Kelvin Kesse

I am the founding partner of Kesse PLLC, a corporate law firm. Prior to founding Kesse PLLC, I worked at the biggest law firms in the country. My practice focuses on securities, capital markets, SEC reporting, emerging companies and startups, and general corporate law. I regularly advise clients on public and private securities offerings and financings, including U.S.-Canadian cross-border offerings and other foreign private issuer offerings. I assist clients with IPOs, Regulation A+ offerings, direct listings, follow-on/secondary offerings, private placements, crowdfunding, private company financings, pre-IPO counseling, SPAC formations, IPOs and business combinations (deSPACs), tender offers, emerging company and startup financings, SEC reporting and compliance and stock exchange listing and compliance. I work with clients all over the U.S. and internationally. My representative transactions include the following: Represented a Nasdaq-listed commercial-stage biotech company in its $345 million IPO, a $244 million follow on offering, and SEC periodic reporting. Represented a Nasdaq-listed developer of a wearable, non-invasive continuous glucose monitor in its IPO. Representing a Nasdaq-listed clinical-stage biopharmaceutical company in its $350 million follow-on public offering. Represented a Nasdaq-listed molecular diagnostics company in its purchase of a private company for approximately $2.15 billion. Represented a biopharmaceutical company in its $5.35 billion business combination. Represented a Nasdaq-listed clinical stage immuno-oncology company in its $2.26 billion acquisition by a public company. Represented a Nasdaq-listed late-stage clinical company in its “At-the-Market” offering and SEC periodic filings. Represented an NYSE-listed life sciences company focused on biopsy diagnostics for the early detection of cancer in its $40.25 million follow-on offering. Represented a biotechnology company in its direct listing.